Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291682 | 0.81 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL20255106 | 0.77 | HRH4 (0.44) | HRH4 | |
| SCHEMBL22601466 | 0.75 | MAPT (0.42) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL20249253 | 0.75 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19001068 | 0.75 | MAPT (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL19001128 | 0.75 | MAPT (0.58) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL19012399 | 0.74 | MAPT (0.59) | CHRNB4CHRNA3MAPTRAB9A | |
| SCHEMBL20414144 | 0.74 | MAPT (0.40) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL22601593 | 0.74 | MAPT (0.59) | CHRNB4CHRNA3MAPTRAB9A | |
| SCHEMBL20414145 | 0.74 | CHRNB4 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CHRNB2 4863/4885CHRNA4 4628/4885CHRNA7 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.